Dr. P. P. Doke. M.D., D.N.B., Ph.D., FIPHA. Professor, Department of Community Medicine, Bharati Vidyapeeth Medical College, Pune

Similar documents
Hosted by Dr. Benedetta Allegranzi, WHO Patient Safety Agency A Webber Training Teleclass

GARP ACTIVITIES IN KENYA. Sam Kariuki and Cara Winters

The Rise of Antibiotic Resistance: Is It Too Late?

IFMSA Policy Proposal Antimicrobial Resistance

Resolution adopted by the General Assembly on 5 October [without reference to a Main Committee (A/71/L.2)]

Development and improvement of diagnostics to improve use of antibiotics and alternatives to antibiotics

WHO's View on IVDs for Addressing AMR

ANTIMICROBIAL RESISTANCE AND NATIONAL ACTION PLAN FOR PRUDENT USE OF ANTIMICROBIALS Egypt, GOVS 2017

Council Conclusions on Antimicrobial Resistance (AMR) 2876th EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS Council meeting

Infection control and antimicrobial resistance in Republic of Moldova. Riga, May 6-8, 2015

Overview of Infection Control and Prevention

A THREE DIMENSIONAL REVIEW ON HUMAN IGNORANCE REGARDING ANTIMICROBIAL RESISTANCE

: "INFECTION CONTROL: WHAT'S COMING IN 2017?" LISA THOMAS RN-BC STATE TRAINING COORDINATOR OFFICE OF LONG TERM CARE

Dr Nata Menabde Executive Director World Health Organization Office at the United Nations Global action plan on antimicrobial resistance

WHO s first global report on antibiotic resistance reveals serious, worldwide threat to public health

Antimicrobial Resistance Initiative

Global Strategies to Address AMR Carmem Lúcia Pessoa-Silva, MD, PhD Antimicrobial Resistance Secretariat

The trinity of infection management: United Kingdom coalition statement

The South African AMR strategy. 3 rd Annual Regulatory Workshop Gavin Steel Sector wide Procurement National Department of Health; South Africa

Antibiotic Resistance. A global view. Katia ISKANDAR RPh, Pharm.D, MHS, AMES, PhD candidate

ANTIMICROBIAL RESISTANCE: GLOBAL BURDEN

Impact of Antimicrobial Resistance on Human Health. Robert Cunney HSE HCAI/AMR Programme and Temple Street Children s University Hospital

Objective 1/20/2016. Expanding Antimicrobial Stewardship into the Outpatient Setting. Disclosure Statement of Financial Interest

Antimicrobial Stewardship in the Hospital Setting

Would you like to be added to our mailing list to receive updates on the development of the global action plan?* Y X N

ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS

American Veterinary Medical Association

Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S.

Prudent use of antimicrobial agents Dairy Sector Initiatives. Robin Condron Dairy Australia

The role of FAO in AMR

MDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC

The Philippine Action Plan to Combat Antibiotic Resistance: One Health Approach

running head: SUPERBUGS Humphreys 1

2016/LSIF/FOR/004 Policies to Promote Patient Access to Innovative Treatments and Combat Antimicrobial Resistance

Action Plan Goal 2 Surveillance and Monitoring Strategies:

The challenge of growing resistance

3/1/2016. Antibiotics --When Less is More. Most Urgent Threats. Serious Threats

Jaipur Declaration on Antimicrobial Resistance

Third Global Patient Safety Challenge. Tackling Antimicrobial Resistance

Overview of Day 1. Dr. Alex Costa World Health Organization. National AMR Workshop Phnom Penh, Cambodia May 2014

International Food Safety Authorities Network (INFOSAN) Antimicrobial Resistance from Food Animals

Antibiotic resistance is one of the biggest threats to global health, food security, and development today.

Summary of the latest data on antibiotic resistance in the European Union

WORLD ANTIBIOTIC AWARENESS WEEK

Australia s response to the threat of antimicrobial resistance

Highlights on Hong Kong Strategy and Action Plan on Antimicrobial Resistance ( ) (Action Plan)

ANTIBIOTIC STEWARDSHIP

MDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta

Antibiotic Resistance A Major Threat to the Sustainable Development Goals

Dr Eleri Davies. Consultant Microbiologist and Infection Control Doctor, Public Health Wales NHS Trust

Evaluation of EU strategy to combat AMR

GUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance

Identifying Medicine Use Problems Using Indicator-Based Studies in Health Facilities

Antimicrobial Resistance, yes we care! The European Joint Action

Government Initiatives to Combat Antimicrobial Resistance (AMR)

Dr Liz Tayler Antimicrobial Resistance Secretariat Global action plan on antimicrobial resistance

Stewardship: Challenges & Opportunities in the Gulf Region

National Action Plan development support tools

AMR in AFRICA. Dr Marc Sprenger Director AMR Secretariat. Antimicrobial resistance in Africa

Responsible Antimicrobial Use

Antimicrobial Resistance Prevention (Action Package: Prevent-1) Putting AMR on the priority list: Sweden Dr. Nils Anders Tegnell, Director, The

The European road map against antimicrobial resistance

Developing New Animal Pharma Products Relevance to antibiotic stewardship in animal agriculture. Karin Hoelzer, DVM, Ph.D.

British Society for Antimicrobial Chemotherapy 53 Regent Place Birmingham B1 3NJ bsac.org.uk antibiotic action.com

New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs

EXPERIENCE ON ANTIMICROBIAL USE AND RESISTANCE IN KENYA

Comments from The Pew Charitable Trusts re: Consultation on a draft global action plan to address antimicrobial resistance September 1, 2014

Tackling the need for new antibacterial drugs

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY REFERENCES: MALTA, COUNTRY VISIT AMR. STOCKHOLM: ECDC; DG(SANTE)/

Lessons learned from the AMR program in Thailand. 29 May 2014

Talk outline. History of resistance. The start of antibiotic resistance: Penicillin. Bacterial evolution vs mankind s ingenuity

India: Policies and perspectives on Antimicrobial Resistance

Antimicrobial Stewardship

USA ACTION PLAN FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA

Antimicrobial resistance

The relevance of Gram-negative pathogens for public health situation in India

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline

Role of the general physician in the management of sepsis and antibiotic stewardship

Clinical and Economic Impact of Urinary Tract Infections Caused by Escherichia coli Resistant Isolates

COMMISSION OF THE EUROPEAN COMMUNITIES

NAP on AMR: Singapore

Healthcare Facilities and Healthcare Professionals. Public

Aerial view of the Faculty of Veterinary Medicine Utrecht

IFMSA Policy Proposal [Antimicrobial Resistance]

Antimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS

OECD WORK ON AMR: TACKLING THE NEGATIVE CONSEQUENCES OF ANTIBIOTIC RESISTANCE ON HUMAN HEALTH. Michele Cecchini OECD Health Division

A Conversation with Dr. Steve Solomon and Dr. Jean Patel on Antimicrobial Resistance June 18 th, 2013

LA-MRSA in the Netherlands: the past, presence and future.

CHALLENGES AND COLLABORATION

Containing Antimicrobial Resistance to Realize the Goals of Universal Health Coverage

Implications for Registration and Approval of Innovative Technologies

Why Don t These Drugs Work Anymore? Biosciences in the 21 st Century Dr. Amber Rice October 28, 2013

Combating Antimicrobial Resistance: A Manufacturing Perspective

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011

IDSA GUIDELINES COMMUNITY ACQUIRED PNEUMONIA

The Economics of Antibiotic Use in U.S. Livestock Agriculture

Combating Antimicrobial Resistance: The Way Forward

Epidemiology and Economics of Antibiotic Resistance

Julaporn Srinha, DVM, MSc Department of Livestock Development (DLD), Ministry of Agriculture and Cooperatives, Royal Thai Government, Thailand

Antimicrobial resistance

Transcription:

Dr. P. P. Doke M.D., D.N.B., Ph.D., FIPHA Professor, Department of Community Medicine, Bharati Vidyapeeth Medical College, Pune 1

Anti microbial resistance is now a global geometrically increasing threat General causes It is natural process of adoption for their survival Its emergence is directly proportional to antimicrobial overuse in humans and foodproducing animals; Globalization and suboptimal infection control facilitate its spread 2

Morbidity and mortality due to communicable diseases is not coming down as desired In fact may increase Financial implications on personal as well community are at high stake It is feared that even it may affect GDP and development 3

Excess cost of hospitalization per patient The mortality may be higher in hospital acquired infections But the magnitude of community acquired infections is higher 4

1. Invest in development of newer effective molecules 2. Antibiotic use policy like rational use of antibiotics, surveillance 3. Non-pharmaceuticals non-specific measures to prevent spread 5

Novel antimicrobials are urgently needed; In recent decades pharmaceutical companies have largely abandoned research on antibiotic development due to their high costs and low yield 6

The scale of the resistance and its impact on human beings is rapidly increasing In 1954, the USA produced just under 1 million kilograms of antimicrobials; annual production in this country alone now (2012-13) exceeds 16 million kg 7

8

9

Indiscriminate use of antibiotics by medical profession Use Growing antibiotic use in the animal sector is resulting in a greater selection of pathogens and is being driven by increased demand for meat and poultry Sub-therapeutic use results in AMR; This resistant microorganisms can be spread to humans Waste water treatment plants serving antibiotic manufacturing facilities have been implicated in the transfer of resistance genes into human microbiota 10

Weak surveillance systems contribute to the spread of drug resistance Improper use of Standard Operating Protocols Sub standard medicines 11

Per capita net national income during 2016-17 is estimated to be Rs. 1,03,007 at current prices The public expenditure on health is estimated to be around 1.2% of the Gross Domestic Product There are1,55,069 Sub Centres; 25,354 Primary Health Centres; and 5,510 Community Health Centres ANM 2,19,980; MPW 53,442; allopathic doctors at PHCs 26,426 9,637 PHCs without laboratory technician 12

1. Ischemic heart disease 12 % 2. Chronic obstructive pulmonary disease 11% 3. Stroke 9% 4. Diarrheal disease 6% 5. Lower respiratory infections 5% 6. Preterm birth complications 4% 7. Tuberculosis 3% 8. Self-inflicted injuries 3% 9. Falls 3% 10.Road injuries 2% 13

Public health impact depends up on The time required for confirmation of agent and resistance (first culture then sensitivity) Complexity The cost Tracking difficulties The clinical and economic benefits of using diagnostic testing 14

Tuberculosis Malaria HIV Influenza Acute respiratory tract infections Diarrheal agents Candidiasis 15

Horizontal measures are not pathogen-specific and include interventions such as improved hand hygiene and enhanced environmental cleaning, both of which have been shown to interrupt pathogen transmission effectively Vertical measures are pathogen-specific and include targeted and universal screening upon hospital admission (e.g., MRSA, ESBL-producing gram-negatives) with or without presumptive isolation, often using novel molecular diagnostic techniques for rapid pathogen detection 16

Treatment without testing the agent and its susceptibility in following common diseases Urinary tract infection Dysentery Upper respiratory tract infection General conflicts Tests are carried out for a group of common antibiotics Clinician expects some specific antibiotics 17

Excellent diagnostics Point of care testing 18

Financial factors are the biggest barriers to bringing the next-generation AMR diagnostics to market Technological advances are barriers to developing next-generation diagnostics Viability and feasibility (1) less expensive tests and more automated analysis of sequence data, (2) increasing the concentration of infectious disease agents from a clinical specimen, and (3) single cell diagnostic testing, like microfluidics 19

Avoiding Unnecessary Antibiotic Use and Optimizing Antibiotic Selection (1) ensuring that tests we have now, as well as future tests, are optimally implemented in clinical settings; (2) developing new diagnostics that improve patient care and antibiotic use; and (3) measuring the impact of diagnostics and antibiotic use 20

Culture independent tests are very useful which provide result faster, sensitive and capacity to detect several agents But important clinical or public health information, such as the susceptibility and resistance to antibiotics may not be available 21

A. Incorporate antimicrobial resistance detection into culture-independent diagnostic tests; B. Collect a specimen for culture-independent tests that is suitable for reflexive testing if the test is positive for a relevant infectious agent; or C. Collect a second specimen for reflexive culture if strategy B is not possible 22

Best example is GeneXpert in tuberculosis, in less than two hours diagnosis and resistance to most important drug Rifampicin confirmed Community expects many more such diagnostics but cost is limiting factor The test must consider the qualifications, experience and working conditions of health manpower 23

Thank you friends 24